

Risk stratification for sudden cardiac death: Is there a clinical role for T wave alternans?

Michael J. Cutler, DO, PhD, David S. Rosenbaum, MD, FHRS

From the Heart and Vascular Research Center, MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio.

The proportion of cardiovascular deaths attributable to sudden cardiac death (SCD) is on the rise. Herein lies the rationale for developing risk stratification strategies to predict who will benefit from prophylactic implantable cardioverter-defibrillator (ICD) implantation. Current guidelines recommend prophylactic ICD therapy in patients with reduced left ventricular ejection fraction (LVEF). However, there are clear limitations in using LVEF alone to decide who should receive an ICD. There is mounting evidence that microvolt-level T-wave alternans (TWA)

is an important marker of arrhythmic risk. TWA is appealing because it noninvasively probes the underlying electrophysiological substrate and has been linked to cellular mechanisms for arrhythmias. This review considers the clinical role of TWA for risk stratification of SCD.

KEYWORDS Repolarization; Electrophysiology; Tachycardia (Heart Rhythm 2009;6:S56–S61) © 2009 Published by Elsevier Inc. on behalf of Heart Rhythm Society.

In recent years, cardiovascular death rates have fallen, yet the proportion of cardiovascular deaths that is attributable to sudden cardiac death (SCD) is on the rise. The most common etiology of SCD is the development of fatal ventricular arrhythmias resulting from the complex structural and electrical remodeling that follows myocardial injury, most commonly secondary to coronary artery disease. Although extensively studied, the factors responsible for initiating ventricular arrhythmias remain poorly understood. Moreover, ventricular tachyarrhythmia events (VTEs) usually occur suddenly, without provocation, and almost invariably result in death. Therefore, efforts aimed at predicting which patients are at highest risk for a VTE and therefore would benefit from primary prevention placement of an implantable cardioverter-defibrillator (ICD) have emerged as the primary paradigm for addressing this major unresolved public health problem.

Risk prediction for SCD and primary prevention ICD therapy

Current primary prevention guidelines recommend prophylactic ICD implantation in patients with reduced left ventricular ejection fraction (LVEF) <0.35 due to prior myocardial infarction or nonischemic cardiomyopathy who are on optimal medical management. These recommendations are based on the fundamental relationship that exists between reduced LVEF and cardiovascular mortality and the

findings of the Multicenter Automated Defibrillator Implantation Trial II (MADIT II) and SCD Heart Failure Trial (SCD-HeFT).^{1,2} Both MADIT II and SCD-HeFT clearly showed that prophylactic ICD therapy saves lives in patients with both ischemic or nonischemic cardiomyopathy and reduced LVEF (i.e., <0.35). Yet there are clear limitations to LVEF as the ideal risk stratification test for deciding whether to implant an ICD for primary prevention of SCD.

LVEF is a direct measure of contractile dysfunction yet only indirectly probes the underlying electrophysiological substrate, and hence it is inherently nonspecific for predicting patients at risk for SCD. For LVEF to be the ideal risk stratification test guiding prophylactic ICD therapy, it should have a very high sensitivity and specificity and a predictive accuracy that remains stable over time.³ Interestingly, both the Maastricht prospective registry and European Autonomic Tone and Reflexes after Myocardial Infarction (ATRAMI) studies suggest that LVEF lacks adequate sensitivity for SCD prediction as both of these studies found that $>50\%$ of all SCDs in these trials occurred in patients with an LVEF >0.35 .^{4,5}

Determining the exact specificity of LVEF as a predictor of SCD risk is challenging because assigning a mechanism to a cause of death in clinical trials has limitations (i.e., are all sudden deaths arrhythmic?). However, the investigators of the Multicenter Unsustained Tachycardia Trial (MUSTT) provided evidence that LVEF has limited specificity when they showed no difference in the percentage of SCD in patients with LVEF <0.30 compared with LVEF 0.30 – 0.40 .⁶ In the ATRAMI study, patients with LVEF <0.35 had no greater risk for SCD than patients with an LVEF >0.35 .⁵ Interestingly, when the ATRAMI investigators combined LVEF <0.35 with the presence of additional risk markers (i.e., history of nonsustained ventricular tachycar-

Research reported in the article was funded by the US National Institutes of Health (NIH) Grant support ROI-HL54807. The author is a Major Consultant to Cambridge Heart Inc. **Address reprint requests and correspondence:** David S. Rosenbaum, M.D., Director, Heart and Vascular Research Center, MetroHealth Campus, Case Western Reserve University, 2500 MetroHealth Drive, Hamman 330, Cleveland, Ohio 44109-1998. E-mail address: drosenbaum@metrohealth.org.

~~proposed to be an important mechanism in the development of Ca^{2+} alternans. For instance, with increasing HR, instability of SR Ca^{2+} release dynamics can develop without beat-to-beat variation in SR Ca^{2+} content, producing Ca^{2+} alternans.¹⁹ It is postulated that the mechanism underlying this phenomenon is secondary to variations in the ability of the RyR to recover from inactivation on a beat-by-beat basis. Finally, TWA can occur at slow HRs under conditions such as long QT syndrome. Although the mechanisms underlying the cardiac alternans at slow HRs are unknown, they are likely related to primary alterations of sarcolemmal ionic currents. In summary, TWA provides insight into cellular dysregulation of repolarization, calcium handling, and abnormalities of sarcolemmal ionic currents.¹~~

Cardiac alternans a common pathway to arrhythmogenesis

A clear benefit of TWA testing is its ability to noninvasively probe the underlying electrophysiological substrate (i.e., repolarization, myocardial calcium cycling, and sarcolemmal ionic currents), yet, is the electrophysiological substrate that TWA probes arrhythmogenic? Recently, repolarization alternans was shown to be a mechanism underlying the genesis of ventricular arrhythmias.⁹ In particular, in an experimental model of TWA, ventricular fibrillation (VF) always precedes the development of discordant repolarization alternans (i.e., alternans occurring with opposite phase between neighboring myocytes). Normally, repolarization alternans develops in a spatially concordant fashion such that all myocytes alternate in the same phase (i.e., long-short-long). Concordant alternans is a marker of changes in the electrophysiological substrate of the heart, yet it is not particularly arrhythmogenic. However, above a critical HR or after an ectopic beat, the phase of repolarization alternans can shift in some cells, producing spatially discordant alternans (i.e., long-short vs. short-long). The onset of discordant alternans markedly amplifies preexisting heterogeneities of repolarization, producing a substrate that is prone to conduction block and, in the structurally normal hearts, the development of VF. In contrast, in the structurally abnormal heart (i.e., scar) or under conditions of prolonged QT interval, discordant alternans produces monomorphic ventricular tachycardia or torsades de pointes, respectively.²⁰

Spatially discordant repolarization alternans clearly produces a substrate that is prone to conduction block and therefore creates a common pathway for the development of a variety of ventricular arrhythmias. However, how discordant repolarization alternans is reflected on the surface ECG remains unclear. It is likely that identifying how discordant repolarization alternans is reflected on the surface ECG could improve the ability of TWA testing to identify patients at risk for SCD.

Methods for measuring TWA in patients

The most widely applied method for noninvasive measurement of TWA uses the spectral method during controlled HR elevation (100–110 bpm). This method was developed

during the 1980s as a way to detect and quantify microscopic alternation in the T wave that is not visible on the surface ECG (i.e., microvolt-level alternans), making it possible to identify and isolate beat-to-beat T-wave fluctuations that repeat every other beat (i.e., alternans) from much larger nonalternating T-wave fluctuations.⁸ In particular, measurement of TWA with the spectral method is most commonly performed during graded exercise using specialized noise-reducing ECG electrodes. The clinical utility of TWA was first established as a marker of arrhythmic risk using the spectral method, when it was shown that TWA develops at a slower HR in patients at greatest risk for SCD when compared with patients at low risk of SCD.⁸ In particular, the development of TWA at HR <110 bpm (i.e., positive TWA) as measured by the spectral method is a specific measure of risk for SCD, whereas the absence of TWA at HR <110 bpm (i.e., negative TWA) seems to indicate a resistance to SCD in a relevant primary prevention population.²¹

Recently, a time-domain measurement technique referred to as the modified moving average (MMA) method has been proposed as an alternative to the spectral method for measuring TWA.^{22,23} The scientific and clinical rationales for MMA have not been established, but it is available on commercially available Holter and stress test systems. This method essentially averages the T-wave amplitude and morphology of odd and even beats over a 15-second period and superimposes the odd and even averages to calculate differences in amplitude. This process repeats itself every 15 seconds, creating a modified moving average of TWA.²³ Early observation studies have shown that TWA measured using the MMA method may be predictive of cardiovascular mortality, yet it is less clear whether it predicts an SCD phenotype.^{22,24} Moreover, there has not been rigorous standardization of the definition of an abnormal test, making it difficult to know exactly how to apply TWA measurements made using the MMA method. For example, currents trial using the MMA method for measuring TWA have used a wide range (5–65 μV) of cut points to identify a positive TWA test.²⁵ Future investigation will need to prospectively evaluate a standardized definition of an abnormal TWA using the MMA method.

TWA as a clinical marker of arrhythmic risk in humans

Initially, most studies linking TWA to SCD were performed in high-risk patients with a history of myocardial infarction and reduced LVEF. However, several recent observational studies have established TWA as a marker of SCD risk and shown that TWA can improve the efficiency of prophylactic ICD therapy in relevant primary prevention populations,^{26–29} while others have not.³⁰ Bloomfield et al²¹ demonstrated that using TWA to further risk stratify a MADIT II–like population decreased the number needed to treat from 18 to seven. Additionally, the recently published Alternans before Cardioverter Defibrillator (ABCD) Trial showed that a TWA-directed risk stratification strategy im-




Figure 1 Prediction of events depends on definition of “events.” Comparison of prospective clinical trials evaluating TWA measured using the spectral analytic method in primary prevention populations in which (1) few patients had ICDs and as a result none or a small fraction ($\leq 15\%$) of the reported endpoint VTEs were ICD detected (low ICD group) or (2) many of the patients had implanted ICDs and the majority of the reported endpoint VTEs were ICD detected (high ICD group). In the low ICD group, comprising 3682 patients, the hazard ratio (HR) associated with a TWA+ versus a TWA- was 13.6 (8.5–30.4), and the annual event rate (AER) among the TWA- patients was 0.3% (0.1%–0.5%). In contrast, in the high ICD group, comprising 2234 patients, the HR was only 1.6 (1.2–2.1), and the AER among the TWA- patients was elevated to 5.4% (4.1%–6.7%). Adapted from Hohnloser et al.³¹

proved the efficiency of prophylactic ICD therapy such that only 11 ICDs needed to be implanted to save one life.²⁸

In contrast, the Microvolt TWA Testing for Risk Stratification of Post-Myocardial Infarction Patients (MASTER) trial failed to demonstrate an increase in ICD-detected VTEs in patients with a nonnegative TWA test when compared with patients with a negative test.³⁰ Interestingly, a nonnegative TWA test did predict an increase in total mortality. It is not clear why a nonnegative TWA test in the MASTER trial was predictive of total mortality but not of ICD-detected VTE, but it may highlight the limitation of ICD-detected VTEs as a surrogate endpoint for SCD. For example, Hohnloser et al.³¹ recently demonstrated that ICD-detected VTE is an unreliable surrogate endpoint for SCD (Figure 1). They identified prospective clinical trials evaluating TWA measured using the spectral analytic method in primary prevention populations and analyzed studies in which (1) few patients had implanted ICDs and as a result none or a small fraction ($\leq 15\%$) of the reported endpoint VTEs were ICD-detected VTEs (low ICD group) or (2) many of the patients had implanted ICDs and the majority of the reported endpoint VTEs were ICD-detected VTEs (high ICD group). Interestingly, in the low ICD group ($n = 3682$), the hazard ratio for SCD associated with a nonnegative versus negative TWA test was 13.6, compared with 1.6 in the high ICD group ($n = 2234$).

Recently, the TWA substudy of SCD-HeFT, which included 19% of the original study population (the mean follow-up was 30 months), suggested that TWA was not predictive of VTEs or mortality.³² However, this study is unique in that it allowed for a comparison of the onset of the TWA signal with the onset of the SCD phenotype in the same primary prevention population. In particular, as dem-

onstrated in Figure 2, mortality rates between TWA-non-negative and TWA-negative patients only begin to differ after 14 months.³³ Interestingly, this is precisely the same time point that the mortality benefit of ICDs occurred, suggesting the onset of the SCD phenotype in the total SCD-HeFT population. This finding provides clinical evidence to support the hypothesis that TWA probes underlying cellular and molecular electrophysiological substrates that are important in producing an SCD phenotype.

Role of TWA in risk stratification for SCD

Clearly, the substrates underlying SCD are complex and dynamic. Therefore, it is unlikely that a single test will be adequate to identify patients who are at the highest risk for SCD and who would therefore benefit from prophylactic ICD therapy. Therefore, the optimal risk stratification model for identifying patients at highest risk for SCD will incorporate multiple risk markers. The benefit of risk stratification strategy that combines multiple risk markers is emphasized in Figure 3. This figure demonstrates that based on recent primary and secondary prevention trials, patients achieve the greatest benefit from ICD therapy for primary prevention guided by a combined risk stratification strategy (i.e., LVEF + invasive EP testing), even better than secondary prevention. In other words, a patient is more likely to benefit from an ICD if he or she has never had an




Figure 2 TWA is a marker of the SCD phenotype. The upper panel shows mortality rates from the main SCD-HeFT. This plot shows that the beneficial effect of ICD therapy in SCD-HeFT begins to emerge between 18 and 24 months (dashed line). The lower panel shows event rates from the TWA substudy of SCD-HeFT. The time base is scaled to match the survival curves from the main SCD-HeFT trial (upper), permitting comparison of the time course of an apparent prognostic TWA signal (i.e., separation of TWA+ and TWA- curves) and the emergence of a detectable SCD phenotype in the same population. These data show that the TWA begins to develop at the same time as the SCD phenotype becomes detectable.³³




Figure 3 ICDs do not benefit all patients with low LVEF: hitting the “sweet spot.” Based on recent primary and secondary prevention trials, patients achieve the greatest benefit from ICD therapy for primary prevention guided by a combined risk stratification strategy (i.e., LVEF + invasive EP testing), which is even greater than the benefit from therapy for secondary prevention. In other words, a patient is more likely to benefit from an ICD if he or she has never had an arrhythmia but has a positive risk marker than if he or she has had a cardiac arrest.

arrhythmia but has positive risk markers than if he or she has had a cardiac arrest. Moreover, there appears to be a potential “sweet spot” for identifying patients who are most likely to benefit from prophylactic ICD therapy. Does TWA have a role in identifying this sweet spot?

Since the ABCD Trial systematically risk stratified all patients by both electrophysiological substrate and TWA testing, it provides us with a unique opportunity to evaluate different risk stratification strategies (i.e., LVEF, TWA, and electrophysiological substrate) for the primary prevention of SCD.²⁸ Figure 4 demonstrates analysis of data from the ABCD Trial testing various risk stratification scenarios asking how a patient would do with prophylactic ICD therapy in terms of the trade-off between therapeutic efficiency (i.e., ICD treated patients without an event) and therapeutic risk (i.e., patients who did not receive an ICD yet had an event). This analysis addresses the question of how risk stratification using combinations of LVEF, TWA, and EP testing can potentially affect the efficiency of primary prevention with ICDs. In particular, if a reduced LVEF alone is the only marker used to guide prophylactic ICD implantation, 93% of patients receiving an ICD will never use their device. In contrast, the addition of other risk markers markedly improves therapeutic efficiency (i.e., overtreatment decreases), with a relatively small increase in the risk of undertreatment. Specifically, the addition of TWA reduced the number of ICD-treated patients without an event to 65%, with only a 1.8% risk that a patient with a VTE is not treated. Moreover, addition of electrophysiological substrate in all patients, a strategy that has been largely abandoned by clinicians, decreases the number of ICD recipients without events to 35% but increases the risk of having a VTE and not being protected to 2.7%. Taken together, risk stratification strategies using multiple risk markers improve therapeutic efficiency 25 times more than it increases risk of

undertreatment, as evidenced by the steep slope of the plot shown in Figure 4. These data support a role for TWA testing as a component of a risk stratification strategy aimed at identifying the aforementioned sweet spot in primary prevention patients. It is important to emphasize that the aforementioned analysis only accounts for 1-year event rates. Also, the apparent “risk” of not treating patients with ICDs was probably overestimated because ICD-related events grossly overestimate clinical events as “appropriate” ICD shocks are not tantamount to a life saved.

Major unresolved questions are, What is the acceptable level of therapeutic efficiency, and What is the acceptable level of undertreatment? The former is a societal question, while the latter is a medical question. To that point, to address the appropriate level of undertreatment, one must also consider competitive risk of morbidity and mortality from nonarrhythmic causes (Figure 4, blue arrow). For example, although an individual patient may meet the criteria for prophylactic ICD therapy, their risk of mortality from progressive heart failure or noncardiovascular causes may offset any mortality benefit obtained from implanting an ICD. Therefore, the final decision of whether to implant




Figure 4 Delivering ICD therapy to those who need it. This figure demonstrates an analysis of data from the ABCD Trial testing various risk stratification scenarios asking how a patient would do with prophylactic ICD therapy in terms of the trade-off between therapeutic efficiency (i.e., ICD-treated patients without an event) and therapeutic risk (i.e., patients who did not receive an ICD yet had an event). If a reduced LVEF alone is the only marker used to guide prophylactic ICD implantation, 93% of patients receiving an ICD will never use their device. In contrast, the addition of TWA reduced the number of ICD-treated patients without an event to 65%, with only a 1.8% risk that a patient with a VTE is not treated. Addition of electrophysiological substrate in all patients, a strategy that has been largely abandoned by clinicians, decreases the number of ICD recipients without events to 35% but increases the risk of having a VTE and not being protected to 2.7%. Taken together, risk stratification strategies using multiple risk markers improve therapeutic efficiency 25 times more than it increases risk of undertreatment, as evidenced by the steep slope of the plot.

an ICD for primary prevention must include an individualized assessment of competitive risk.

In conclusion, there are clear advantages to TWA as a risk stratification tool for identifying patients for prophylactic ICD therapy. (1) TWA measured on the surface ECG is linked to an arrhythmia mechanism arising from abnormal intracellular calcium cycling. (2) Patients with reduced LVEF who have a negative TWA test are at considerably lower risk for SCD. (3) In contrast to LVEF that only indirectly probes electrophysiological substrate, TWA probes underlying electrophysiological substrate and has been linked to cellular mechanisms of arrhythmogenesis. (4) Unlike many other risk markers, TWA appears to track arrhythmia susceptibility independent of heart failure progression and is comparably predictive in patients with both ischemic and nonischemic cardiomyopathy. (5) TWA can guide selection of appropriate patients for ICD therapy, particularly when competitive mortality risks are present or patients are reluctant to receive ICD therapy. Going forward, randomized clinical trials are required that use risk stratification strategies, such as TWA, to determine therapies such as ICDs.

References

- Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med* 2005;352:225–237.
- Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med* 2002;346:877–883.
- Buxton AE. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction $< \text{or} = 30\%$ should receive an implantable cardioverter-defibrillator. *Circulation* 2005;111:2537–2549.
- Gorgels AP, Gijssbers C, de Vreede-Swagemakers J, Lousberg A, Wellens HJ. Out-of-hospital cardiac arrest—the relevance of heart failure. The Maastricht Circulatory Arrest Registry. *Eur Heart J* 2003;24:1204–9.
- La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes after Myocardial Infarction) Investigators. *Lancet* 1998;351:478–484.
- Buxton AE, Lee KL, Hafley GE, Wyse DG, Fischer JD, Lehman MH, et al, and MUSTT Investigators: Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease—an analysis of patients enrolled in the Multicenter Unsustained Tachycardia Trial. *Circulation* 2002;106:2466–2472.
- Narayan SM. T-wave alternans and the susceptibility to ventricular arrhythmias. *J Am Coll Cardiol* 2006;47:269–281.
- Rosenbaum DS, Jackson LE, Smith JM, Garan H, Ruskin JN, Cohen RJ. Electrical alternans and vulnerability to ventricular arrhythmias. *N Engl J Med* 1994;330:235–241.
- Pastore JM, Girouard SD, Laurita KR, Akar FG, Rosenbaum DS. Mechanism linking T-wave alternans to the genesis of cardiac fibrillation. *Circulation* 1999;99:1385–1394.
- Herring H. Experimentelle Studien an Säugetieren über das Electrocardiogramm. *Ztschr f. ges. exper. Med* 1909;7:363.
- Lewis T. Notes upon alternation of the heart. *Q J Med* 1910;4:141–144.
- Hirata Y, Kodama I, Iwamura N, Shimizu T, Toyama J, Yamada K. Effects of verapamil on canine Purkinje fibers and ventricular muscle fibers with particular reference to the alternation of action potential duration after a sudden increase in driving rate. *Cardiovasc Res* 1979;13:1–8.
- Saitoh H, Bailey J, Surawicz B. Action potential duration alternans in dog Purkinje and ventricular muscle fibers. *Circulation* 1989;80:1421–1431.
- Laurita KR, Katta R, Wible B, Wan X, Koo MH. Transmural heterogeneity of calcium handling in canine. *Circ Res* 2003;92:668–675.
- Wan X, Laurita KR, Pruvot E, Rosenbaum DS. Molecular correlates of repolarization alternans in cardiac myocytes. *J Mol Cell Cardiol* 2005;39:419–428.
- Chudin E, Goldhaber JJ, Weiss J, Kogan B. Intracellular Ca²⁺ dynamics and the stability of ventricular tachycardia. *Biophys J* 1999;77:2930–2941.
- Cutler MJ, Wan X, Hajjar RJ, Rosenbaum DS. Targeted SERCA2a gene over-expression identifies mechanism and potential therapy for arrhythmogenic cardiac alternans. *Circulation* 2007;116:II–217 (abstract).
- Xie LH, Sato D, Garfinkel A, Qu Z, Weiss JN. Intracellular Ca alternans: coordinated regulation by sarcoplasmic reticulum release, uptake, and leak. *Biophys J* 2008;95:3100–3110.
- Picht E, DeSantiago J, Blatter LA, Bers DM. Cardiac alternans do not rely on diastolic sarcoplasmic reticulum calcium content fluctuations. *Circ Res* 2006;99:740–748.
- Cutler MJ, Rosenbaum DS. Explaining the clinical manifestations of T wave alternans in patients at risk for sudden cardiac death. *Heart Rhythm* 2009;6: S22–28.
- Bloomfield DM, Steinman RC, Namerow PB, Parides M, Davidenko J, Kaufman ES, et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. *Circulation* 2004;110:1885–1889.
- Cox V, Patel M, Kim J, Liu T, Sivaraman G, Narayan SM. Predicting arrhythmia-free survival using spectral and modified-moving average analyses of T-wave alternans. *Pacing Clin Electrophysiol* 2007;30:352–358.
- Verrier RL, Nearing BD, La Rovere MT, Pinna GD, Mittleman MA, Bigger JT, et al, and ATRAMI Investigators. Ambulatory electrocardiogram-based tracking of T wave alternans in postmyocardial infarction patients to assess risk of cardiac arrest or arrhythmic death. *J Cardiovasc Electrophysiol* 2003;14:705–711.
- Sakaki K, Ikeda T, Miwa Y, Miyakoshi M, Abe A, Tsukada T, et al. Time-domain T-wave alternans measured from Holter electrocardiograms predicts cardiac mortality in patients with left ventricular dysfunction: a prospective study. *Heart Rhythm* 2009;6:332–7.
- Amit G, Costantini O, Rosenbaum DS. Can we alternate between T-wave alternans testing methods? *Heart Rhythm* 2009;6:338–340.
- Bloomfield DM, Bigger JT, Steinman RC, Namerow PB, Parides MK, Curtis AB, et al. Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. *J Am Coll Cardiol* 2006;47:456–463.
- Chow T, Keriakes D, Bartone C, Booth T, Schloss EJ, Waller T, et al. Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy. *J Am Coll Cardiol* 2006;47:1820–1827.
- Costantini O, Hohnloser SH, Kirk MM, Lerman BB, Baker JH 2nd, Sethuraman B, et al. The Alternans before Cardioverter Defibrillator (ABCD) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention. *J Am Coll Cardiol* 2009;53(6):471–479.
- Exner DV, Kavanagh KM, Slawnych MP, Mitchell LB, Ramadan D, Aggarwal SG, et al. Noninvasive risk assessment early after a myocardial infarction the REFINE study. *J Am Coll Cardiol* 2007;50:2275–2284.
- Chow T, Keriakes DJ, Onufer J, Woelfel A, Gursoy S, Peterson BJ, et al. Does microvolt T-wave alternans predict ventricular tachyarrhythmias in patients with ischemic cardiomyopathy and prophylactic defibrillators? The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients) Trial. *J Am Coll Cardiol* 2008;52:1607–1615.
- Hohnloser SH, Ikeda T, Cohen RJ. Evidence regarding clinical use of microvolt T-wave alternans. *Heart Rhythm* 2009;6:S36–44.
- Gold MR, Ip JH, Costantini O, Poole JE, McNulty S, Mark DB, et al. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. *Circulation* 2008;118:2022–2028.
- Rosenbaum DS. T-wave alternans in the sudden cardiac death in heart failure trial population: signal or noise? *Circulation* 2008;118:2015–2018.